NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis → Is this Nvidia's secret weapon? (From Manward Press) (Ad) Free NLSP Stock Alerts $0.14 0.00 (-0.72%) (As of 01:32 PM ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.4052-Week Range$0.11▼$1.53Volume70,322 shsAverage Volume440,669 shsMarket Capitalization$1.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NLS Pharmaceutics alerts: Email Address Ad Manward PressIs this Nvidia's secret weapon?You've likely heard about Nvidia's incredible success in AI. But there's an untold story that could be even bigger.Click here to discover the AI chip company About NLS Pharmaceutics Stock (NASDAQ:NLSP)NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More NLSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLSP Stock News HeadlinesMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMay 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.March 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 14, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 11, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceMarch 11, 2024 | finance.yahoo.comNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing ComplianceFebruary 23, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqMay 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.February 14, 2024 | seekingalpha.comNLSP NLS Pharmaceutics Ltd.January 20, 2024 | finance.yahoo.comNotice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 12, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing RequirementsDecember 23, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider TradesDecember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary SharesDecember 5, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and DatesDecember 1, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.November 27, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaNovember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary Shares NLSPNovember 16, 2023 | msn.comWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% TodayNovember 16, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanOctober 19, 2023 | finance.yahoo.comNLS Pharmaceuticals to Reschedule Company Update on Strategic DiscussionsOctober 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 5, 2023 | msn.comNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95September 14, 2023 | msn.comMaxim Group Downgrades NLS Pharmaceutics (NLSP)August 28, 2023 | benzinga.comNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder LetterJuly 3, 2023 | finance.yahoo.comNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study ProtocolSee More Headlines Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book0.49Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.70 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Alexander Zwyer M.B.A. (Age 55)President, CEO & Director Comp: $1.07MDr. George Apostol M.D. (Age 51)Chief Medical Officer and Global Head of Research & Development Comp: $154kDr. Eric Konofal M.D. (Age 57)Ph.D., Co-Founder & Chief Scientific Officer Ms. Elena Thyen-PighinChief Financial OfficerDr. Christian C. Wenger Dr. iur. (Age 60)L.L.M., Ph.D., General Counsel Key CompetitorsContext TherapeuticsNASDAQ:CNTXLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZPharvarisNASDAQ:PHVSProcaps GroupNASDAQ:PROCView All Competitors NLSP Stock Analysis - Frequently Asked Questions Should I buy or sell NLS Pharmaceutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NLSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLSP, but not buy additional shares or sell existing shares. View NLSP analyst ratings or view top-rated stocks. How have NLSP shares performed in 2024? NLS Pharmaceutics' stock was trading at $0.5899 at the start of the year. Since then, NLSP shares have decreased by 76.8% and is now trading at $0.1370. View the best growth stocks for 2024 here. Are investors shorting NLS Pharmaceutics? NLS Pharmaceutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 75,100 shares, a decline of 77.6% from the March 31st total of 335,800 shares. Based on an average trading volume of 561,900 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.3% of the shares of the stock are short sold. View NLS Pharmaceutics' Short Interest. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NLSP) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsIs this Nvidia's secret weapon?Manward PressCould Your Accounts Be Frozen?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits“Crash Insurance” For Your RetirementUnstoppable ProsperityMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
